Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Intrinsic Value
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. [ Read More ]
The intrinsic value of one
SUPN
stock under the Base Case scenario is
39.4
USD.
Compared to the current market price of 29.31 USD,
Supernus Pharmaceuticals Inc
is
Undervalued by 26%.
Supernus Pharmaceuticals Inc's market capitalization is 1.6B USD.
SUPN stock price is 29.31 USD.
SUPN stock price (29.31 USD) is 26% less than its Intrinsic Value (39.4 USD).
SUPN stock price (29.31 USD) is 30% less than its Relative Value (41.84 USD). Open Relative Valuation
SUPN has upside potential of 41% compared to the average analyst price target.
Open Wall St Estimates
SUPN has positive Net Income for the last twelve months.
SUPN's Revenue is forecast to grow at a rate of 5% per year over the next 3 years.
SUPN has positive Operating Income for the last twelve months.
SUPN's Revenue has been growing by 5% per year for the last 3 years.
SUPN has positive three-year average ROE (Return on Equity): 8%. The company is efficient at transforming stockholders' equity into net income.
SUPN's Revenue has dropped by 9% over the past 12 months.
SUPN has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
SUPN's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
SUPN's ROE (Return on Equity) for the past 12 months is very low and is equal to 0%.
SUPN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 12% to 1%.
SUPN's ROE (Return on Equity) has significantly decreased in the last 3 years from 16% to 0%.
SUPN's short-term assets (493m USD) exceed its short-term liabilties (290m USD).
SUPN has positive Free Cash Flow for the last twelve months.
SUPN generates enough operating income (15m USD) to cover interest payments on its debt (2m USD).
SUPN has positive Gross Profit for the last twelve months.
SUPN's Altman Z-Score is very high and is equal to 3.66.
SUPN's long-term assets (1B USD) exceed its long-term liabilties (356m USD).
SUPN's D/E (Debt to Equity) is very low and is equal to 0.
Valuation Backtest
Supernus Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
SUPN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Supernus Pharmaceuticals Inc
Balance Sheet Decomposition
Supernus Pharmaceuticals Inc
| Current Assets | 493.1m |
| Cash & Short-Term Investments | 254.9m |
| Receivables | 144.2m |
| Other Current Assets | 94.1m |
| Non-Current Assets | 784.6m |
| Long-Term Investments | 16.6m |
| PP&E | 42.5m |
| Intangibles | 716.9m |
| Other Non-Current Assets | 8.5m |
| Current Liabilities | 290.2m |
| Accounts Payable | 2m |
| Accrued Liabilities | 231.9m |
| Other Current Liabilities | 56.4m |
| Non-Current Liabilities | 66m |
| Other Non-Current Liabilities | 66m |
Earnings Waterfall
Supernus Pharmaceuticals Inc
|
Revenue
|
607.5m
USD
|
|
Cost of Revenue
|
-83.8m
USD
|
|
Gross Profit
|
523.7m
USD
|
|
Operating Expenses
|
-508.8m
USD
|
|
Operating Income
|
14.9m
USD
|
|
Other Expenses
|
-13.6m
USD
|
|
Net Income
|
1.3m
USD
|
Free Cash Flow Analysis
Supernus Pharmaceuticals Inc
SUPN Profitability Score
Profitability Due Diligence
Supernus Pharmaceuticals Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Supernus Pharmaceuticals Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
SUPN Solvency Score
Solvency Due Diligence
Supernus Pharmaceuticals Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Supernus Pharmaceuticals Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SUPN
is 41.31 USD
with a low forecast of 38.38 USD and a high forecast of 45.15 USD.
Ownership
SUPN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SUPN Price
Supernus Pharmaceuticals Inc
| Average Annual Return | 3.9% |
| Standard Deviation of Annual Returns | 26.87% |
| Max Drawdown | -62% |
| Market Capitalization | 1.6B USD |
| Shares Outstanding | 55 301 300 |
| Percentage of Shares Shorted | 13.27% |
Company Profile
Supernus Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 575 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Contact
IPO
Employees
Officers
The intrinsic value of one
SUPN
stock under the Base Case scenario is
39.4
USD.
Compared to the current market price of 29.31 USD,
Supernus Pharmaceuticals Inc
is
Undervalued by 26%.
You don't have any saved screeners yet
